CA19-9 — the standard pancreatic cancer blood test — actually helps the cancer spread to the liver

CA19-9 — the standard pancreatic cancer blood test — actually helps the cancer spread to the liver

CA19-9 is the most commonly used blood biomarker for pancreatic cancer, elevated in most patients and used to monitor disease progression. But this study reveals that CA19-9 isn't merely a passive indicator — it actively promotes liver metastasis.

Using mouse models engineered to express human CA19-9 (since mice lack this carbohydrate antigen), researchers showed that CA19-9 expression markedly increased liver metastatic burden. The mechanism: CA19-9 on tumor cell surfaces binds to E-selectin on liver blood vessel endothelial cells, helping tumor cells stick to the liver and survive there — both promoting initial seeding and subsequent outgrowth.

This functional role is significant because it identifies CA19-9 — already measured in essentially every pancreatic cancer patient — as a potential therapeutic target, not just a biomarker. Blocking the CA19-9/E-selectin interaction could theoretically reduce the liver metastases that are the primary driver of death in pancreatic cancer.

Key Findings

• CA19-9 expression in syngeneic mouse PDAC cells markedly increased liver metastatic burden
• CA19-9 promotes both metastatic seeding and subsequent outgrowth in the liver
• Mechanism involves CA19-9 enhancing tumor cell adhesion to liver endothelial cells via E-selectin
• Both in vitro adhesion assays and in vivo splenic injection models confirmed the finding
• CA19-9 transitions from passive biomarker to active metastatic promoter in this model

Implications

These findings reframe CA19-9 from a monitoring biomarker to a functional driver of metastasis. Therapeutic strategies targeting CA19-9 or its E-selectin receptor interaction could complement existing treatments to reduce liver metastasis — the primary cause of death in pancreatic cancer patients. Anti-selectin therapies already exist in other contexts and could be repurposed.

Caveats

Preprint, not peer reviewed. Mouse models with engineered CA19-9 expression may not fully reflect the complexity of human pancreatic cancer. Clinical validation of CA19-9 as a therapeutic target requires further study. Summary based on abstract only.

Source: bioRxiv — 2026-04-10